心力衰竭的管理：產品、系統及商機

本報告已在2011年07月19日停止出版。

簡介

專門提供最新醫藥品及醫療技術的資訊分析與對策的 MedMarket Diligence（總公司：美國加州） ，出版了有關心力衰竭管理產品、系統及商機的調查報告書 "Products, Systems and Opportunities in Heart Failure Management"。

該報告書針對目前以及開發階段的心力衰竭預防、監控、診斷、管理上的標準療程、產品以及系統等，進行全面性的評估，並詳述心力衰竭的發生率、初期治療、專科醫生的診斷現況，同時分析治療方法、檢驗機器與醫藥產品、疾病管理公司所提供的療程系統，並且兼論醫院與家庭對心力衰竭病人的管理狀況。

該報告書包含 40 筆附加資料，全文共 225 頁，章節摘錄如下。

摘要

第1章　說明

• 本報告書的範圍
• 心力衰竭的背景
• 臨床的背景

第2章　心力衰竭臨床外的問題

• 關於費用的問題

第3章　心力衰竭的管理方法

• 現在使用的產品
• 心力衰竭的管理與治療上的新技術

第4章　心力衰竭的診斷、管理、預防以及血液循環動態評估上的監控

• 心力衰竭的預防、治療以及血液循環的管理與血管機能的作用
• 現有產品的方法/產品名稱/利用法的動向

第5章　心力衰竭的心疾患管理企業之角色

• 疾病管理療程的進化
• 心力衰竭的疾病管理作用之現況與未來

第6章　附錄

• 心疾患管理企業一覽表
• 心力衰竭管理企業及治療產品企業一覽表

目錄

This report will be a thorough assessment of the current and emerging clinical practice, products and systems for the prevention, screening, diagnosis and management of heart failure. The Report will detail the incidence and prevalence of heart failure, projecting the trend as a result of demographics, intervention or other changes to the population of patients. The Report will detail the current approaches applied by physicians (primary care & cardiologists) and healthcare systems to heart failure. The report will accordingly address clinician and system approaches, detailing the practices, products, and services in use and under development. Products addressed will include monitoring, medicines/drugs and devices. The Report will provide a detailed review of heart failure programs in place through disease management companies, and hospital, home care and outpatient programs. The Report will detail the status of research at a representative number of hospitals toward improving heart failure programs. The report will detail the current and projected market for products in heart failure management encompassing diagnostics, monitoring products, drugs/medicines and devices, with breakdown at these major category levels.

Table of Contents

Executive Summary

Section 1: Introduction

• 1.1 Scope of report
• 1.2 Heart Failure Background
• 1.3 Clinical Background
  • 1.3.1 Description of Symptoms
  • 1.3.2 Treatment Guidelines Under Review
    • 1.3.2.1 New AHA/HFSA Guidelines Previewed at 2002 HFSA Scientific Meeting
    • 1.3.2.2 Heart Failure Specialist, Cardiologist, Primary Care--Impact of Specialist Care on Patient Performance Measures
  • 1.3.3 Statistics
    • 1.3.3.1 Incidence, prevalence
    • 1.3.3.2 Hospital discharges
    • 1.3.3.3 Hospital readmissions
  • 1.3.4 Heart Failure Programs
    • 1.3.4.1 CV Disease Management Companies
    • 1.3.4.2 Hospital Programs
    • 1.3.4.3 Home Care Programs
    • 1.3.4.4 Outpatient Center Programs
      • 1.3.4.4.1 Role of Primary Care, Family Practitioner
      • 1.3.4.4.2 Role of Cardiologist
      • 1.3.4.4.3 PharmD involvement
      • 1.3.4.4.4 Role of Other Physician specialty(ies)
      • 1.3.4.4.5 Role of CV disease management companies

Section 2: Heart Failure-Non-Clinical Issues

• 2.1 Costs and cost-related issues:
  • 2.1.1 Hospitalizations
    • 2.1.1.1 Lost revenues in hospitals due to implementation of a heart failure program which reduced readmissions
    • 2.1.1.2 Net income loss in hospitals due to emergent readmissions of heart failure patients under DRG 127
    • 2.1.1.3 Increase in hosptial revenues from ancillary procedures
    • 2.1.1.4 Effects of nationwide nursing shortage.
    • 2.1.1.5 Efforts underway to manage costs
    • 2.1.1.6 Role of advanced home monitoring in reduction of CHF-related admissions
    • 2.1.1.7 Efforts underway to improve care
    • 2.1.1.8 HFSA�fs efforts
    • 2.1.1.9 Achieving cardiac excellence project
    • 2.1.1.10 Communication and friction between the heart failure community and the primary care community
  • 2.1.2 Chronic care
  • 2.1.3 Reimbursement

Section 3: Methods in Managing Heart Failure

• 3.1 Products Currently in use
  • 3.1.1 Monitoring products
    • 3.1.1.1 CO2 rebreathing
    • 3.1.1.2 Heart catheterization
    • 3.1.1.3 Noninvasive hemodynamic monitoring
    • 3.1.1.4 Networked electronic questionnaires
    • 3.1.1.5 Call-in voice mail
    • 3.1.1.6 Weight scales
  • 3.1.2 Medical treatments
    • 3.1.2.1 Diuretics
    • 3.1.2.2 Inotropes
    • 3.1.2.3 Vasodilators
  • 3.1.3 Medical devices treatments
    • 3.1.3.1 Implantable Cardioverter Defibrillators (ICDs)
    • 3.1.3.2 Resynchronization Therapy
• 3.2 New Technologies in the Management and Treatment of Heart Failure

Section 4: Hemodynamic assessments in the Diagnostics, Management, Prevention and Monitoring of Heart Failure

• 4.1 The Role of Hemodynamics and Vascular Function Assessment in Prevention, Treatment and Management of Heart Failure
• 4.2 Current Products Methods/Products/Usage Trends
  • 4.2.1 CO2 Rebreathing
  • 4.2.2 Heart Catheterization
  • 4.2.3 Newer Hemodynamic Measurement Monitoring Methods/Products
    • 4.2.3.1 Ambulatory Blood Pressure Monitoring
    • 4.2.3.2 Impedance Cardiography
    • 4.2.3.3 Implantable Monitoring
    • 4.2.3.4 Noninvasive Measurements/Monitoring
    • 4.2.3.5 Lower-Extremity Bioimpedance
  • 4.2.4 Markets and Opportunities
  • 4.2.5 Products and Competition
  • 4.2.6 Market Forecast 2001-2006
  • 4.2.7 Company Profiles
    • 4.2.7.1 A&D Medical-LifeSource
    • 4.2.7.2 AtCor Medical
    • 4.2.7.3 CardioDynamics International Corporation
    • 4.2.7.4 CardioMEMS
    • 4.2.7.5 CVP Diagnostics
    • 4.2.7.6 Data Sciences International
    • 4.2.7.7 Hypertension Diagnostics, Inc.
    • 4.2.7.8 IEM Americas
    • 4.2.7.9 Medtronic, Inc.
    • 4.2.7.10 Pulse Metric, Inc.
    • 4.2.7.11 Remon Medical Technologies
    • 4.2.7.12 Rozinn Medical
    • 4.2.7.13 Spacelabs Medical division of Instrumentarium
    • 4.2.7.14 SORBA Medical Systems, Inc.
    • 4.2.7.15 SunTech Medical Instruments
    • 4.2.7.16 VivoMetrics, Inc.
    • 4.2.7.17 VSM MedTech Ltd.
    • 4.2.7.18 Wantagh Incorporated

Section 5 THE ROLES OF CARDIOVASCULAR DISEASE MANAGEMENT COMPANIES IN HEART FAILURE

• 5.1 The Evolution of Disease Management Programs
• 5.2 Current and Future Roles of DM in Heart Failure
  • 5.2.1 Guidelines
  • 5.2.2 Program Goals
  • 5.2.3 Company Involvement in Reduction of CHF-Related Hospital Admissions and Readmissions
  • 5.2.4 Assessment Tools Used in Home Monitoring of CHF Patients
    • 5.2.4.1 Call Centers
    • 5.2.4.2 Interactive Voice Response Systems
    • 5.2.4.3 Telemonitoring Devices
    • 5.2.4.4 Enabling Technologies for Home Monitoring of CHF Patients
  • 5.2.5 Review of Market Opportunities and Competition - Company Profiles
    • 5.2.5.1 Alere Medical
    • 5.2.5.2 American Healthways
    • 5.2.5.3 Cardiocom Multi-Disease Management
    • 5.2.5.4 CorSolutions Medical, Inc.
    • 5.2.5.5 CyberCare, Inc.
    • 5.2.5.6 Disease Management Association of America
    • 5.2.5.7 Disease Management Purchasing Consortium & Advisory Counsel
    • 5.2.5.8 Health Alert, Inc.
    • 5.2.5.9 Health Hero Network, Inc.
    • 5.2.5.10 HomMed, LLC
    • 5.2.5.11 I-trax, Inc.
    • 5.2.5.12 LifeMasters Supported SelfCare, Inc.
    • 5.2.5.13 Landacorp, Inc
    • 5.2.5.14 McKesson Health Solutions, LLC
    • 5.2.5.15 Philips Medical (Agilent /HP)
    • 5.2.5.16 Protocol Driven Healthcare, Inc.
    • 5.2.5.17 Qmed Interactive Heart Management

Section 6: APPENDICES

• 6.1 Company Listing-Cardiovascular Disease Management
• 6.2 Company Listing-Heart Failure Management and Treatment Product Manufacturers

相關商品

MedMarket Diligence發行的醫療設備相關市場調查報告書

全球脊椎手術（2011年）：產品、技術、市場以及機會（2010∼2020年）

Worldwide Spine Surgery 2011: Products, Technologies, Markets & Opportunities, 2010-2020

價格 : US $ 3750

出版日期 : 2011年07月

全球電燒技術市場（2009∼2019年）：產品、技術、市場、企業及技術

Ablation Technologies Worldwide Market, 2009-2019: Products, Technologies, Markets, Companies and Opportunities

價格 : US $ 2850

出版日期 : 2010年06月

全球傷口管理（2008年至2017年）：北美、歐洲、日本、其他各國的既有產品及新興產品、技術、市場

Worldwide Wound Management, 2009: Established and Emerging Products, Technologies and Markets in the U.S., Europe, Japan and Rest of World

價格 : US $ 2850

出版日期 : 2009年09月

Email Alert(Email 通知) - 最新市場調查報告書

GII 將每天定期更新最新市場調查報書資訊，選擇您有興趣的市場分類，我們將用Email的方式讓您收到最新訊息!